Skip to main content
. 2018 Mar 25;109(4):1207–1219. doi: 10.1111/cas.13536

Figure 6.

Figure 6

In vivo antitumor activity of anlotinib against a panel of tumor xenografts. A, U‐87MG, (B) Caki‐1, (C) SK‐OV‐3, and (D) Calu‐3 tumor‐bearing mice were orally given vehicle (n = 12) or the indicated doses of anlotinib or sunitinib (n = 6) daily. In SK‐OV‐3 and Calu‐3 xenograft models, anlotinib at 6 mg/kg was orally given daily for only 9 d. Data are presented as means ± SEM. **P < .05, **P < .01 vs vehicle